Comprehensive microbiome-care service for humans and pets; drug-discovery seeds.
| Date | Round | Amount |
|---|---|---|
| Oct 2023 | Series B KINS, a microbiome-care company, raised about JPY 1.5B in a second close of its Series B (including debt). | $10M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.